(Pursuant to Article L.233-8 II of the French Commercial Code and articles 221-1 and 223-16 of the General Regulations of the Autorité des Marchés Financiers)
Regulatory News:
As of May 31, 2012, shares and voting rights outstanding of Essilor (Paris:EI), the world leader in ophthalmic optics, broke down as follows:
| Â | Â | May 31, 2012 |
| Shares outstanding | 212,717,125 | |
| Exercisable voting rights | 223,680,300 | |
| Total voting rights, based on all outstanding shares, including shares stripped of their voting rights* | 228,559,705 |
(*)Shares held by the Company, either in treasury or under the liquidity contract.
About Essilor The world's leading ophthalmic optics company, Essilor designs, manufactures and markets a wide range of lenses to improve and protect eyesight. Its corporate mission is to enable everyone around the world to access lenses that meet his or her unique vision requirements. To support this mission, the Company allocates around €150 million to research and development every year, in a commitment to continuously bring new, more effective products to market. Essilor's flagship brands are Varilux®, Crizal®, Definity®, Xperio®, Optifog™ and Foster Grant®. It also develops and markets equipment, instruments and services for eyecare professionals. Essilor reported consolidated revenue of €4.2 billion in 2011 and employs around 48,700 people in some 100 countries. It operates 19 plants, a total of 390 prescription laboratories and edging facilities, as well as several research and development centers around the world. For more information, please visit www.essilor.com. The Essilor share trades on the NYSE Euronext Paris market and is included in the CAC 40 and Euro Stoxx 50 indexes. Codes and symbols:ISIN:FR0000121667; Reuters:ESSI.PA; Bloomberg:EI:FP. |
Contacts:
Investor Relations and Financial Communications
Phone: +33
(0)1 49 77 42 16
